Table 3: CLINICAL data of representative MSCs therapy for IBD from Pubmed in the past decade.

SourcesDiseaseTherapeutic schedulePhaseNumberEvaluationOutcomeReference

1Allogeneic-
BMMSCs
UCa single dose of
(1.5-2) x 108 intravenously
II4424 months34 (72.7%) of patients achieved the clinical
and morphological indices of inflammatory activity↓.
[112]

2Allogeneic-
ADMSCs
Perianal fistulizing CDa single dose of
1.2 x 108 intralesionally
III21224 weeks50% of patients treated with ADMSCs achieved combined remission.[113]

3Allogeneic-
ADMSCs
Perianal fistulizing CDa single dose intralesionally
If 2 x 107 failed, 4 x 107 subsequently
II2424 weeks69.2% of patients achieved the number of draining fistulas↓
56.3% of patients achieved complete fistula closure of the treated.
30% of patients achieved complete closure of all existing fistula tracts.
[114]

4Allogeneic-
BMMSCs
Perianal fistulizing CDa single dose of 1 × 107,
3 × 107, or 9 × 107 intralesionally
II216, 12, and 24 weeksno severe adverse events.
3 × 107 MSCs appeared to promote healing of perianal fistulas
[115]

5Allogeneic-MSCsLuminal CDa single dose of
2 × 106 /kg weekly for
4 weeks intravenously
II1642 days15 patients CDAI score ↓ from 370 to 203 at day 42[116]

6Autologous-BMMSCsLuminal CDtwo doses of
1-2×106 intravenously,
7 days apart
I100, 6 weeks3 patients CDAI score ↓ at 6 weeks[117]

7Autologous-ADMSCsPerianal fistulizing CDlocal injection,2×107I1224 weeks9 of 12 patients had complete clinical healing by 3 months,
10 of 12 patients (83.3%) had complete clinical healing at 6 months
[118]

8Autologous-ADMSCsPerianal fistulizing CDgroup 1: 1 × 107 cells/ml. After 4 weeks, if safe,
group 2: 2 × 107 cells/ml. After 4 weeks, if safe,
group 3: 4 × 107 cells/ml
I>98 weeks2 patients in group 2 showed complete healing
and 3 patients in group 3 showed complete healing at week 8.
[119]

9Autologous-BMMSCsCDa single dose of
2 × 107, 5 × 107,
or 10 × 107 cells/kg intravenously
I122 weeksSingle infusion of BMMSCs propagated ex vivo
using human platelet lysate-supplemented media
was safe and feasible at the doses of up to 10 million cells/kg
[120]

10Autologous-ADMSCsPerianal fistulizing CD3 × 107 cells per centimeter lengthII438 weeks27/33 patients (82%) had complete fistula healing.
Of 27 patients, 23 patients (88%) sustained complete closure
[121]